About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Multi-academic Center Study of Xofigo Patients

NCT03419442·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bayer

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Received at least one dose of radium-223 after mCRPC diagnosis
Received at least one prescription or dose of chemotherapy for treatment of mCRPC

You may not be if

\- No documented visceral metastasis at initiation of radium-223

The record

StatusCompleted

PhaseNo phase

Taking part150

StartedDec 2018

UpdatedOct 22, 2020

Conditions

Prostate Cancer, Castration Resistant

Where1

Bayer US
Whippany, New Jersey, United States

Clareo Health | Multi-academic Center Study of Xofigo Patients